Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Neumora Therapeutics, Inc. (NMRA : NSDQ)

• Company Description    Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. Its therapeutic pipeline currently consists of clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Neumora Therapeutics Inc. is based in WATERTOWN, Mass. Number of Employees: 96

• Price / Volume Information    Yesterday's Closing Price: $1.85 Daily Weekly Monthly 20 Day Moving Average: 1,455,592 shares Shares Outstanding: 185.28 (millions) Market Capitalization: $342.78 (millions) Beta: 3.02 52 Week High: $3.65 52 Week Low: $0.66 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.04% -21.09% 12 Week -47.89% -51.82% Year To Date 3.35% -4.98%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 260 ARSENAL PLACE SUITE 1 - WATERTOWN,MA 02472 USA ph: 857-760-0900 fax: - investors@neumoratx.com http://www.neumoratx.com

• General Corporate Information    Officers Paul L. Berns - Chief Executive Officer Michael Milligan - Chief Financial Officer Kristina M. Burow - Director Matthew K. Fust - Director Alaa Halawa - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 640979100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/05/26 Share - Related Items Shares Outstanding: 185.28 Most Recent Split Date: (:1) Beta: 3.02 Market Capitalization: $342.78 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.24 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.98 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.85 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 28.57% vs. Previous Quarter: 14.29% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -181.70 12/31/25 - -146.41 09/30/25 - -113.81 ROA 03/31/26 - -119.15 12/31/25 - -111.57 09/30/25 - -96.90 Current Ratio 03/31/26 - 5.09 12/31/25 - 5.87 09/30/25 - 6.85 Quick Ratio 03/31/26 - 5.09 12/31/25 - 5.87 09/30/25 - 6.85 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 0.38 12/31/25 - 0.62 09/30/25 - 0.82 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.75 12/31/25 - 0.52 09/30/25 - 0.15 Debt-to-Capital 03/31/26 - 42.83 12/31/25 - 34.43 09/30/25 - 12.89

Powered by Zacks Investment Research ©